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Blastic plasmacytoid dendritic cell neoplasms
(BPDN) are exceeding rare T-cell neoplasms that
carry a dismal prognosis. Today, the exact etiology of
the disease is unclear, and to our knowledge, no
cases of BPDN have been reported at the site of
vaccination injection. Additionally, all currently
described cases described have dismal prognosis,
and, to our knowledge, there are no reports of such
lesions responding to topical steroid treatment.
Herein, we present an unusual case of BPDN
occurring at an influenza vaccination site that sub-
sequently resolved after high-potency topical steroid
treatment.CASE REPORT
A 71-year-old white man with no significant
medical history presented with a 5.0-cm nontender,
erythematous, and scaling plaque with an indurated
border on the left upper arm. The lesion appeared
at the site of an influenza vaccination that he
received 7 days prior. The patient denied systemic
symptoms and any such reaction with previous
vaccinations. The initial clinical suspicion was
that of an injection site hypersensitivity reaction.
A punch biopsy was performed, and a topical
high-potency steroid, diflorasone diacetate 0.05%,
was prescribed.
The biopsy found an atypical dense lymphoid
infiltrate in the papillary and reticular dermis. A grenz
zone was present. The infiltrate shows prominent
perivascular distribution (Fig 1). The individualthe Departments of Dermatopathology and Pathology,
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10029. E-mail: Jonathan.YaoMD@gmail.com.lymphocytes had hyperchromatic nuclei with
irregular nuclear contour and nucleoli (Fig 2).
Crush artefact was present at the periphery of the
biopsy section.
Immunohistochemical profiling found the lesion
to be diffusely CD41 and CD561 (Fig 3). Most of the
lesional cells were also CD1231 and TdT1 (Fig 3).
Repeat CD123 staining found more intense and
diffuse positivity. Admixed were rare CD791 B cells.
Tests for myeloperoxidase, CD34, MUM1, PAX5,
CD3, CD10, CD21, kappa, and lambda were
negative. Epstein Barr virus in situ hybridization
results were also negative. In addition to these
markers, an outside hospital found that our lesion
was TCL11 and CD117 and muramidase negative.
After histologic and immunoprofiling of CD41,
CD561, TCL1, and CD1231, a diagnosis of BPDN
was rendered. Differential diagnosis included
extramedullary myeloid sarcoma and an acute
leukemia with ambiguous lineage. Absence of
myeloperoxidase excluded myeloid sarcoma, and
absence of CD34, myeloperoxidase, CD117, and
muramidase ruled out acute leukemia. This diag-
nosis was confirmed by a senior hematopathologist
and at major cancer center. At the 2-week follow up,
the patient reported that the entire lesion hadJAAD Case Reports 2015;1:203-6.
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Fig 1. Dense atypical lymphohistiocytic infiltrate occu-
pying the dermis with a grenz zone. (Original magnifica-
tion: 3100.)
Fig 2. On higher magnification, atypical lymphocytes
show hyperchromatic nuclei with irregular nuclear
contour and nucleoli. (Original magnification: 3400.)
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lack of clinical evidence of disease, radiation therapy
was delivered at the site. At the time of this report,
bone marrow and blood involvement were not
found and leukemia was excluded, but watchful
follow-up is necessary.DISCUSSION
BPDN is a rare and aggressive hematologic dis-
ease, the etiology, incidence, clinical presentation,
and treatment strategies of which are still being
elucidated. Derived from precursors of plasmacytoid
dendritic cells, BPDN is categorized under ‘‘acute
myeloid leukemia and related precursor neoplasms’’
by the 2008 World Health Organization classifica-
tion.1,2 Most patients are elderly men, with a male to
female ratio of 2.2:1 to 3:1 and a median age of
approximately 67 years.2,3 Pediatric cases have also
been reported, and the clinical progression appears
to be less aggressive with a more favorable prog-
nosis.4 No racial or ethnic preferences have been
found. The incidence of BPDN among cutaneous
lymphomas is 1.4%.5Patients most commonly present with cutaneous
lesions, ranging from isolated or few purplish
nodules, bruiselike macules, and disseminated
macules and papules to lymphadenopathy.2
Pulmonary and central nervous system symptoms
may also occur. Cytopenia, splenomegaly, hepato-
megaly, and other symptoms of leukemic dissemi-
nation signify disease progression. Fulminant
leukemia indicates terminal illness. Regardless of
the initial clinical presentation, prognosis is poor.
Among patients presenting with primarily cutaneous
symptoms, with or without lymph node, central
nervous system, or bone marrow involvement,
median overall survival was 12 months.2 Among
patients presenting with leukemic involvement, with
or without cutaneous symptoms, median overall
survival was 8.7 months.3
Patients receiving treatment in the early
cutaneous phase of disease, with isolated or few
lesions, may have more favorable outcome. Poor
prognostic indicators include advanced age and
clinical staging.2,3 Children with BPDN have
improved median overall survival when given the
same treatment as adults.4 Given the low incidence
of the disease, no standard of care has been
established for BPDN, and determinations of treat-
ment efficacy rely on retrospective case or registry
studies. Induction therapy includes focal radio-
therapy, chemotherapy, and glucocorticosteroids to
address cutaneous lesions. Late-stage disease
treatments include cyclophosphamide, hydroxydau-
nomycin, vincristine, prednisone and hyperfractio-
nated cyclophosphamide, vincristine, doxorubicin,
dexamethasone alternating with methotrexate and
cytarabine, but relapse occurs within months of
remission on average.6 Patients that undergo
hematopoietic stem cell transplantation (HSCT),
often used to maximize consolidation of response
or after relapse, show the greatest promise for
long-term response, with better survival curves and
overall survival rates than patients that only had
conventional therapies. These determinations are
primarily anecdotal from case studies, with small
sample sizes and populations skewed toward
younger males, so robust statistical evaluations are
lacking.7-9 In one study of 47 patients with BPDN,
overall survival in HSCT patients was significantly
higher than that in non-HSCT patients (31.3 months
vs 12.8 months).9
Misdiagnosis is common, leading to delayed
treatment, as BPDN can be morphologically and
clinically indistinguishable from leukemia cutis
and acute myeloid leukemia. Immunophenotypic
analysis, morphology, and clinical details are used
for definitive diagnosis. As of now, there is no
Fig 3. The infiltrate is diffusely and strongly positive for CD4 and CD56, diffusely positive for
CD123, and only focally positive CD79a. (Original magnification: 3200.)
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pathologic diagnosis of BPDN. The most
characteristic markers for BPDN are CD4, CD56,
CD123, CD303, and TCL1. In one retrospective study,
diagnosis by immunophenotype was considered
definite when patients coexpressed at least 4 of
these main markers.10 In our case, positivity in 4
of these 5 main markers, along with exclusion of
myloid sarcoma and acute leukemia of ambiguous
origin from negative markers as described above,
allowed for diagnostic completeness.
The etiology and pathogenesis of BPDN remains
largely unknown. Studies into normal physiologic
counterparts to malignant BPDN cells yielded
plasmacytoid dendritic cells and plasmacytoid
dendriticelike cells as candidates.11,12 A review of
molecular data found that abnormalities in chromo-
somes 5, 9, 12, 13, and 15 are nonuniformly involved
in pathogenesis, suggesting a diversity of genetic
mutations that can dysregulate oncogenic pathways
in BPDN.6 Epstein-Barr virus is not associated with
BPDN.1
A review of literature found that BPDN can
manifest with a variety of cutaneous phenotypes.
Julia and et al2 observed a pattern of few lesions in
early disease, progressing to cutaneous dissemina-
tion in late disease. The lesions ranged in type and
color, described as nodes, patches, plaques, andtumors, of brown or violaceous appearance.2 Given
the variety of its cutaneous manifestations and low
incidence, BPDN can be mistaken for eczema or
lupus erythematosus, leading to delay in appropriate
treatment.13,14
In the English-language literature, there are no
reports, to our knowledge, of BPDN occurring at
the vaccination site. In addition, BPDN also carries
a poor prognosis, and the regression of our
patient’s lesion with topical high potency steroid
makes our case novel and intriguing. The diagnosis
of this lesion is dependent on histologic and
immunologic evaluation. To date, there is no spe-
cific molecular test to confirm a diagnosis of BPDN.
Therefore, based on the current standards, a diag-
nosis of BPDN was made on our biopsy. However,
the atypical presentation and behavior of our case
raises the question if our lesion was indeed a
distinct presentation of BPDN that carries a good
prognosis or was a BPDN-like reaction to the
vaccination. At the time of this report, the benign
clinical course of this case is highly uncharacteristic
of BPDN. Regardless, given the possibility of true
BPDN and the prognosis it carries, any such lesion
with characteristic histology and immunopheno-
type should be met with extreme suspicion, and
treatment measures appropriate to BPDN should be
considered.
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